Platelet inhibition strategies in percutaneous coronary intervention: competition or coopetition?
Publication
, Journal Article
Tcheng, JE; Campbell, ME
Published in: J Am Coll Cardiol
October 1, 2003
Duke Scholars
Published In
J Am Coll Cardiol
DOI
ISSN
0735-1097
Publication Date
October 1, 2003
Volume
42
Issue
7
Start / End Page
1196 / 1198
Location
United States
Related Subject Headings
- Tyrosine
- Tirofiban
- Ticlopidine
- Platelet Glycoprotein GPIIb-IIIa Complex
- Platelet Aggregation Inhibitors
- Myocardial Infarction
- Immunoglobulin Fab Fragments
- Humans
- Drug Administration Schedule
- Combined Modality Therapy
Citation
APA
Chicago
ICMJE
MLA
NLM
Tcheng, J. E., & Campbell, M. E. (2003). Platelet inhibition strategies in percutaneous coronary intervention: competition or coopetition? J Am Coll Cardiol, 42(7), 1196–1198. https://doi.org/10.1016/s0735-1097(03)00945-8
Tcheng, James E., and Mark E. Campbell. “Platelet inhibition strategies in percutaneous coronary intervention: competition or coopetition?” J Am Coll Cardiol 42, no. 7 (October 1, 2003): 1196–98. https://doi.org/10.1016/s0735-1097(03)00945-8.
Tcheng JE, Campbell ME. Platelet inhibition strategies in percutaneous coronary intervention: competition or coopetition? J Am Coll Cardiol. 2003 Oct 1;42(7):1196–8.
Tcheng, James E., and Mark E. Campbell. “Platelet inhibition strategies in percutaneous coronary intervention: competition or coopetition?” J Am Coll Cardiol, vol. 42, no. 7, Oct. 2003, pp. 1196–98. Pubmed, doi:10.1016/s0735-1097(03)00945-8.
Tcheng JE, Campbell ME. Platelet inhibition strategies in percutaneous coronary intervention: competition or coopetition? J Am Coll Cardiol. 2003 Oct 1;42(7):1196–1198.
Published In
J Am Coll Cardiol
DOI
ISSN
0735-1097
Publication Date
October 1, 2003
Volume
42
Issue
7
Start / End Page
1196 / 1198
Location
United States
Related Subject Headings
- Tyrosine
- Tirofiban
- Ticlopidine
- Platelet Glycoprotein GPIIb-IIIa Complex
- Platelet Aggregation Inhibitors
- Myocardial Infarction
- Immunoglobulin Fab Fragments
- Humans
- Drug Administration Schedule
- Combined Modality Therapy